13 Nov Treatment for SARS-CoV-2 with oral investigational medicine (pills) in adult outpatients
The EIDD-2801 study is testing an oral investigational medicine for the treatment of COVID-19, the illness caused by SARS-CoV-2 coronavirus. In this study, approximately 15 participants will be randomized to receive EIDD-2801 or Placebo orally, twice a day for 5 days, with follow-up by the study team for a total of 28 days that will include 6 in-person clinic visits.
This study is being conducted at Fred Hutch’s COVID-19 Clinical Research Center in Seattle, WA (as one of the study’s site locations) and will enroll adults overall who have recently tested positive for SARS-CoV-2and are symptomatic. This is a phase 1, randomized, double-blind, placebo-controlled study.
If you qualify and decide to join the clinical treatment study, you will be compensated for your time. Transportation to the center for appointments is also available, at no charge to the participant, and can be discussed at the time of screening. The Study Team will not share participant’s private health information or citizenship information at any point, Social Security information is not needed, and Health Insurance is not needed and is not charged.
– Adults 18 years of age or older at the time of signing the informed consent
– Laboratory confirmed SARS-CoV-2 infection, with test results within past 72 hours of enrollment
– Symptomatic – experiencing at least one of the following symptoms: fever/chills; OR lower respiratory cough, upper respiratory congestion, sore throat, shortness of breath, or loss of sense of smell or taste
– Able to attend all appointments at the Fred Hutch CCRC in Seattle, WA within the study schedule. vehicular transportation to the CCRC for appointments is also available, at no charge to the participant, and can be discussed at the time of screening with the study team
COVID-19 Clinical Research Center Team
(206) 667-7100 x_____
Additional Study Details
Full Study Title
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of EIDD-2801 to Eliminate SARS-CoV-2 Viral RNA Detection in Persons with COVID-19
Dr. Michael Boeckh, Fred Hutch
Dr. Elizabeth Duke, Fred Hutch
Accepts Healthy Volunteers?
Fred Hutch COVID-19 Clinical Research Center
820 Minor Ave N Entrance B
Seattle, Washington 98109